SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The study is to explore the efficacy and safety of SCT200 with SCT-I10A or SCT200 combined
with paclitaxel/docetaxel in the treatment of recurrent/metastatic head and neck squamous
cell carcinoma.